Literature DB >> 33546518

Pharmacokinetics and Pharmacodynamics of Salvinorin A and Salvia divinorum: Clinical and Forensic Aspects.

Andreia Machado Brito-da-Costa1, Diana Dias-da-Silva1,2, Nelson G M Gomes1,3, Ricardo Jorge Dinis-Oliveira1,2,4, Áurea Madureira-Carvalho1,3.   

Abstract

Salvia divinorum Epling and Játiva is a perennial mint from the Lamiaceae family, endemic to Mexico, predominantly from the state of Oaxaca. Due to its psychoactive properties, S. divinorum had been used for centuries by Mazatecans for divinatory, religious, and medicinal purposes. In recent years, its use for recreational purposes, especially among adolescents and young adults, has progressively increased. The main bioactive compound underlying the hallucinogenic effects, salvinorin A, is a non-nitrogenous diterpenoid with high affinity and selectivity for the k-opioid receptor. The aim of this work is to comprehensively review and discuss the toxicokinetics and toxicodynamics of S. divinorum and salvinorin A, highlighting their psychological, physiological, and toxic effects. Potential therapeutic applications and forensic aspects are also covered in this review. The leaves of S. divinorum can be chewed, drunk as an infusion, smoked, or vaporised. Absorption of salvinorin A occurs through the oral mucosa or the respiratory tract, being rapidly broken down in the gastrointestinal system to its major inactive metabolite, salvinorin B, when swallowed. Salvinorin A is rapidly distributed, with accumulation in the brain, and quickly eliminated. Its pharmacokinetic parameters parallel well with the short-lived psychoactive and physiological effects. No reports on toxicity or serious adverse outcomes were found. A variety of therapeutic applications have been proposed for S. divinorum which includes the treatment of chronic pain, gastrointestinal and mood disorders, neurological diseases, and treatment of drug dependence. Notwithstanding, there is still limited knowledge regarding the pharmacology and toxicology features of S. divinorum and salvinorin A, and this is needed due to its widespread use. Additionally, the clinical acceptance of salvinorin A has been hampered, especially due to the psychotropic side effects and misuse, turning the scientific community to the development of analogues with better pharmacological profiles.

Entities:  

Keywords:  Salvia spp.; hallucinogens; herbal highs; opioid receptors; pharmacodynamics; pharmacokinetics

Year:  2021        PMID: 33546518      PMCID: PMC7913753          DOI: 10.3390/ph14020116

Source DB:  PubMed          Journal:  Pharmaceuticals (Basel)        ISSN: 1424-8247


  191 in total

1.  Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen.

Authors:  Zeynep S Teksin; Insong J Lee; Noble N Nemieboka; Ahmed A Othman; Vijay V Upreti; Hazem E Hassan; Shariq S Syed; Thomas E Prisinzano; Natalie D Eddington
Journal:  Eur J Pharm Biopharm       Date:  2009-06       Impact factor: 5.571

2.  Correlates of Salvia divinorum use in a national sample: findings from the 2009 National Survey on Drug Use and Health.

Authors:  Jason A Ford; William C Watkins; Lindsey Blumenstein
Journal:  Addict Behav       Date:  2011-06-28       Impact factor: 3.913

3.  New neoclerodane diterpenoids isolated from the leaves of Salvia divinorum and their binding affinities for human kappa opioid receptors.

Authors:  David Y W Lee; Zhongze Ma; Lee-Yuan Liu-Chen; Yulin Wang; Yong Chen; William A Carlezon; Bruce Cohen
Journal:  Bioorg Med Chem       Date:  2005-10-01       Impact factor: 3.641

4.  Salvinorin A attenuates early brain injury through PI3K/Akt pathway after subarachnoid hemorrhage in rat.

Authors:  Juan Sun; Xiaomei Yang; Yan Zhang; Weiguang Zhang; Jianfei Lu; Qin Hu; Renyu Liu; Changman Zhou; Chunhua Chen
Journal:  Brain Res       Date:  2019-05-21       Impact factor: 3.252

5.  Case series: Salvia divinorum as a potential addictive hallucinogen.

Authors:  Joseph El-Khoury; Evelyne Baroud
Journal:  Am J Addict       Date:  2018-04

Review 6.  Kappa opioids and the modulation of pain.

Authors:  Bronwyn Kivell; Thomas E Prisinzano
Journal:  Psychopharmacology (Berl)       Date:  2010-04-07       Impact factor: 4.530

7.  An immunochromatographic assay for rapid etection of salvinorin A.

Authors:  Madan Kumar Paudel; Osamu Shirota; Seiichi Sakamoto; Satoshi Morimoto; Hiroyuki Tanaka
Journal:  J Immunoassay Immunochem       Date:  2017-05-05

8.  Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.

Authors:  Yulin Wang; Kang Tang; Saadet Inan; Daniel Siebert; Ulrike Holzgrabe; David Y W Lee; Peng Huang; Jian-Guo Li; Alan Cowan; Lee-Yuan Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2004-09-21       Impact factor: 4.030

9.  Salvinorins D-F, new neoclerodane diterpenoids from Salvia divinorum, and an improved method for the isolation of salvinorin A.

Authors:  Thomas A Munro; Mark A Rizzacasa
Journal:  J Nat Prod       Date:  2003-05       Impact factor: 4.050

10.  Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans.

Authors:  Matthew W Johnson; Katherine A MacLean; Michael J Caspers; Thomas E Prisinzano; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-02-15       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.